Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
about
The changing landscape of biosimilars in rheumatologyThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.CT-P13 in the treatment of rheumatoid arthritis.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Interchangeability of Biosimilars: A European Perspective.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator.Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.Comparative effectiveness of the biosimilar CT-P13.Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.Serum sickness-like disease after switching to biosimilar infliximab.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
P2860
Q26766515-E956B13A-E5AA-4B99-A3B7-6FFD3435406BQ30397234-F8C45F14-240C-40A6-8B8D-6C140D8932F8Q33726030-4D03F0B4-2A37-4E58-ADFD-EBC6495F96C0Q33881234-BF2374F1-B322-48F8-A597-78E0E205091AQ38676104-FD6868C0-D64B-4242-B66C-68642FED138EQ38960108-E74F44BA-9760-444B-8567-B8E7FC37EE80Q38977625-9C8B1039-86C2-4B9C-90E6-A5CFEA7F98BFQ39000780-DF241FF0-32C0-48CC-90A3-342CDD23A4E0Q39051341-12E47831-F1A3-462F-9733-A470968B8775Q47132312-0D2ECFB7-4AE3-494B-8509-5FED92A3ED18Q47368079-B4DF7494-B6F1-4CAA-AED0-5C72725AF1DDQ47418286-81BAC2CD-7003-4504-B513-3586E31C9237Q47662808-B70E0291-2637-47F2-9770-2F9D595215C6Q49608190-8116D3EA-7254-461B-BE08-2E14E6B64A85Q49979586-5C088F7B-1605-45AD-AD4C-9E549F3158CEQ50065301-D420F57E-AE33-4732-9A23-61A76EF0FC0EQ51397182-FD63EEB7-3AB9-436F-BD15-91EE1FAF13F1Q55008089-FFA0717F-EF61-49AB-8CD7-4EF12E9D4147
P2860
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@en
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@nl
type
label
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@en
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@nl
prefLabel
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@en
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@nl
P2093
P2860
P1476
Antibodies to infliximab in Re ...... eactivity towards biosimilars.
@en
P2093
Ainara Maguregui
Ainhoa Ruiz Del Agua
Alejandro Balsa
Ana Martínez-Feito
Antonio Martínez
Chamaida Plasencia
Daniel Nagore
Dora Pascual-Salcedo
Francisca Llinares-Tello
José Rosas
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-208684
P407
P577
2016-03-10T00:00:00Z